FDA Guidance May Jumpstart Digital Therapeutics Market

The digital therapeutics market has had its share of ups and downs. While there’s excitement around the potential to bolster patient outcomes, few products have been fully embraced by patients, providers, or insurers. A big stumbling block is the absence of reliable clinical evidence.

But the industry may be at a turning point. The Food and Drug Administration in October announced the creation of a digital health advisory committee charged with offering input on new health technology, including digital therapeutics. Something that may have a more immediate impact is...